Abstract
It is generally accepted that the clinical efficacy of monoamine oxidase inhibitors (MAOI) is related to inhibition of this enzyme. In order to evaluate the predictive ability of monoamine oxidase-A inhibition for therapeutic efficacy, the start of treatment effects of moclobemide, a selective, reversible monoamine oxidase-A inhibitor, on plasma concentrations of monoamines and monoamine metabolites were determined. The plasma levels of 3,4-dihydroxy-phenylglycol (DHPG, deaminated metabolite of noradrenaline), 5-hydroxyindoleacetic acid (5-HIAA, deaminated metabolite of serotonin), 3,4-dihydroxyphenylacetic acid and homovanillic acid (DOPAC and HVA, deaminated metabolites of dopamine),l-dihydroxyphenylalanine (l-dopa) and noradrenaline were investigated and related to treatment outcome. This was a randomized double blind parallel group study in 47 patients with criteria of major depression according to DSM III R. Moclobemide 300 mg/day, 450 mg/day or 600 mg/day was administered continuously for 6 wecks. Plasma concentrations of monoamine metabolites and monoamines were determined just before treatment by moclobemide, 4 h after the first dose, 24 h after the first dose, before the first dose on day 7, and 4 h after the first dose on day 7. Each moclobemide dose improved depression as measured by MADRS (Montgomery-Asberg Depression Rating scale) but there was no difference between the three doses. Moclobemide dose-dependently reduced plasma concentration of DHPG,l-dopa and HVA. No dose-dependent treatment effect was observed for plasma 5-HIAA, noradrenaline and DOPAC. The clinical outcome as defined by the final MADRS score was not related to any start of treatment changes in plasma monoamine metabolites reflecting inhibition of MAO-A. It is concluded that monoamine oxidase-A inhibition at the beginning of the treatment does not predict clinical outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn revised. Washington, DC
Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ (1990) Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase—A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 30: 805–816
Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ (1995) Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 38: 756–761
Bresnahan DB, Pandey GN, Janicak PG, Sharma R, Boshes RA, Chang SS, Gierl BL, Davis JM (1990) MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 51: 47–50
Brown MJ, Monks NJ (1983) Plasma dihydroxyphenylglycol concentration: a simple, sensitive and specific index of monoamine oxidase—A activity in vivo. Br J Clin Pharmacol 15: 599P
Davidson J, McLeod M, White HL (1978) Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. Am J Psychiatry 135: 470–472
Dingemanse J, Korn A, Pfefen JP, Güntert TW (1992) Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology 106: S46-S48
Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986) Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their response to inhibition of monoamine oxidase. Clin Chem 32: 2030–2033
Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ (1988) Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst 24: 1–14
Eisenhofer G, Bush JE, Cannon RI, Stull R, Kopin IJ, Goldstein DS (1989) Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans. J Clin Endocrinol Metab 68: 247–255
Eisenhofer G, Pecorella W, Pacak K, Hooper D, Kopin IJ, Goldstein DS (1994) The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. J Auton Nerv Syst 50: 93–107
Finberg JPM, Pacak K, Kopin IJ, Goldstein DS (1993) Chronic inhibition of monoamine oxidase type A increases noradrena-line release in rat frontal cortex. Naunyn-Schmiedeberg’s Arch Pharmacol 347: 500–505
Freeman H (1993) Moclobemide. Lancet 342: 1528–1532
Fritze J, Laux G, Sofic E, Koronakis P, Schoerlin MP, Riederer P, Beckmann H (1989) Plasma moclobernide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacology 99: 252–256
Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106: S6-S14
Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 333–364
Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH (1989) Inhibition of monoamine oxidase by moclobemide: effects on monoamine, metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27: 243–255
Lecrubier Y, Guelfi JD (1990) Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand Suppl 360: 18–23
Maier W, Philipp M, Buller R, Schlegel S (1987) Reliability and validity of the Newcastle Scale in relation to ICD-9 classification. Acta Psychiatr Scand 76: 619–627
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389
Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P, Caille P (1995) Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 35: 633–643
Ravaris CL, Nies A, Robinson DS, Ives JO, Lamborne KR, Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 33: 347–350
Risby ED, Hsiao JK, Sunderland T, Agren H, Rudorfer MV, Potter WZ (1987) The effects of antidepressants on the cerebrospinal fluid homovalillic acid/5-hydroxyindolacetic acid ratio. Clin Pharmacol Ther 42: 547–554
Youdim MBH, Finberg JPM, Kuhn DM, Wolf WA (1984) The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin. In: Paton W et al. (eds) IUPHA 9th International Congress of Pharmacology, Proceedings. MacMillan Press, London 2: 203–209
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Radat, F., Berlin, I., Spreux-Varoquaux, O. et al. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. Psychopharmacology 127, 370–376 (1996). https://doi.org/10.1007/BF02806017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02806017